The National Institute of General Medical Sciences (NIGMS), one of the National Institutes of Health, supports all research featured in this digest. Although only the lead scientists are named, coworkers and other collaborators also contributed to the findings.
In This Issue... November 17, 2010
High res. image (JPG, 51KB)
Hermann Steller • Rockefeller University
What look like yellow-green flames show a mitochondrion (blue) in its death throes. Its red-soaked neighbors are already dead. The image comes from research on programmed cell death, or apoptosis, revealing that two proteins, Reaper and Hid (green), join together and travel to mitochondria, the cell's power plants. There, they trigger the release of cytochrome c (red), which in turn activates a fatal chain reaction. The yellow areas show the chromatic mix of the Reaper-Hid complex and cytochrome c. Read more...
Kazuko Nishikura • The Wistar Institute
People infected with Epstein-Barr virus (EBV) can harbor the pathogen inside their cells for years after the illness. The dormant virus is a major barrier to clearing the infection, which can resurge to trigger diseases like cancer. Scientists have now shown that EBV keeps a low profile during this phase by deploying microRNAs, snippets of RNA that silence its genes. By targeting EBV's microRNAs, we may be able to arouse the virus, exposing it to the immune system and eliminating it from the body. Read more...
Caption: Two Epstein-Barr virus particles (top left; bottom right). Credit: Liza Gross. High res. image (JPG, 127KB)
Jeffrey Skolnick • Georgia Institute of Technology
Like a busy shipping port, cells are crowded with different molecules
that maneuver around each other to reach their destination. So what
physical forces have the most impact on these molecular movements?
A new simulation suggests that it's the wakes and eddies the molecules
generate as they move through the cellular water. The results come
from a small-scale study—15 types of molecules packed at realistic
concentrations inside a model E. coli cell—but they
set the stage for whole-cell simulations to study everything from
cell division to drug side effects. Read
Caption: Proteins, RNA, DNA and other molecules crowd cells. Credit: Jeffrey Skolnick. High res. image (JPG, 63KB)
Tricia Serio • Brown University
Researchers have thought that how fast mad cow disease and its human variant, Creutzfeldt-Jakob disease, spread in the body depends mainly on the number of misfolded proteins called prions that accumulate in cells. A new study based on the mathematical modeling of prion movement between yeast cells suggests that the size of those prion clumps matters more: Big clumps can't spread from cell to cell. The findings could improve understanding of prion diseases in mammals and help inform future treatment strategies.
Caption: Prion clumps tagged fluorescent green in an infected yeast cell. Credit: Serio Lab. High res. image (JPG,27KB )
Gregory Stephanopoulos • MIT
A pacific yew tree provides enough ingredient to produce just one
dose of the cancer-fighting drug Taxol. Now scientists have found
a way to metabolically engineer E. coli to produce mass
quantities of taxadiene, the precursor to Taxol. By adding two plant
genes to a compound found in E.coli, they discovered that
they could use the bacteria to synthesize taxadiene. This finding
could make Taxol cheaper and lead to new methods for generating
enough material to develop therapeutic variations of the anti-cancer
Caption: A close-up view of E. coli. High res. image (JPG,52KB)
To read additional news items, visit NIGMS News, Twitter or Facebook. To check out other free NIGMS publications, go to the order form. To subscribe or unsubscribe, visit https://public.govdelivery.com/accounts/USNIGMS/subscriber/new?topic_id=USNIGMS_3. You may also subscribe to the RSS version of Biomedical Beat by selecting this XML link and following your news reader's instructions for adding a feed.
For more information about Biomedical Beat, please contact the editor, Emily Carlson, in the NIGMS Office of Communications and Public Liaison at email@example.com or 301-496-7301. The text in this newsletter is not copyrighted, and we encourage its use or reprinting.